HSBC Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

HSBC Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56,900	Closed	-$1.78M	–	3216
2025 Q4	$1.78M	Buy	56,900 +16,000	+39%	+$394K	﹤0.01%	1621
2025 Q3	$826K	Buy	40,900 +9,200	+29%	+$162K	﹤0.01%	1876
2025 Q2	$533K	Sell	31,700 -9,200	-22%	-$148K	﹤0.01%	2121
2025 Q1	$630K	Buy	+40,900	New	+$731K	﹤0.01%	1966
2022 Q1	–	Sell	-50,100	Closed	-$401K	–	3479
2021 Q4	$401K	Hold	50,100	–	–	﹤0.01%	2598
2021 Q3	$488K	Sell	50,100 -3,000	-6%	-$28.1K	﹤0.01%	2260
2021 Q2	$526K	Sell	53,100 -27,000	-34%	-$286K	﹤0.01%	2133
2021 Q1	$924K	Sell	80,100 -50,500	-39%	-$579K	﹤0.01%	1647
2020 Q4	$1.25M	Buy	130,600 +79,500	+156%	+$762K	﹤0.01%	1565
2020 Q3	$460K	Buy	+51,100	New	+$541K	﹤0.01%	1995
2020 Q2	–	Sell	-29,000	Closed	-$260K	–	2852
2020 Q1	$260K	Hold	29,000	–	–	﹤0.01%	2138
2019 Q4	$289K	Hold	29,000	–	–	﹤0.01%	2577
2019 Q3	$200K	Hold	29,000	–	–	﹤0.01%	2870
2019 Q2	$268K	Hold	29,000	–	–	﹤0.01%	2385
2019 Q1	$455K	Hold	29,000	–	–	﹤0.01%	2152
2018 Q4	$447K	Hold	29,000	–	–	﹤0.01%	2151
2018 Q3	$625K	Sell	29,000 -87,400	-75%	-$2.03M	﹤0.01%	1932
2018 Q2	$2.83M	Buy	116,400 +97,400	+513%	+$1.99M	0.01%	1372
2018 Q1	$324K	Buy	19,000 +15,000	+375%	+$293K	﹤0.01%	2154
2017 Q4	$76K	Buy	+4,000	New	+$60.2K	﹤0.01%	1997
2017 Q3	–	Sell	-2,000	Closed	-$66K	–	2332
2017 Q2	$66K	Hold	2,000	–	–	﹤0.01%	2143
2017 Q1	$66K	Buy	+2,000	New	+$68.3K	﹤0.01%	2078
2014 Q1	–	Sell	-50,000	Closed	-$2M	–	1799
2013 Q4	$2M	Hold	50,000	–	–	0.01%	1123
2013 Q3	$1.89M	Hold	50,000	–	–	0.01%	1111
2013 Q2	$1.96M	Buy	+50,000	New	+$1.95M	0.01%	932

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's TEVA Position: Q1 2026 in Review

HSBC Holdings increased its Teva Pharmaceuticals (TEVA) stake by 57% in Q1 2026, buying an estimated $11.3M and bringing the position to 961,140 shares worth $28.8M. The position accounts for 0.02% of the portfolio, ranked #653.

HSBC Holdings first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $29.9M in Q3 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

HSBC Holdings held 961,140 shares of Teva Pharmaceuticals worth $28.8M as of Q1 2026.
HSBC Holdings bought 350,534 Teva Pharmaceuticals shares in Q1 2026, an estimated $11.3M.
Teva Pharmaceuticals made up 0.02% of HSBC Holdings's portfolio in Q1 2026, its #653 holding.
HSBC Holdings first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
HSBC Holdings's Teva Pharmaceuticals position peaked at $29.9M in Q3 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.